For a deep tech founder approaching a Series A raise, intellectual property is not a legal checkbox—it is the asset investors are pricing. Venture capitalists evaluating deep technology companies scrutinize the strength and scope of the patent portfolio, whether trade secrets have been protected with reasonable measures, and whether the company actually owns everything it claims to sell. A portfolio that satisfies those three tests becomes a fundraising weapon; one that fails any of them becomes a red flag that can cost leverage at the term sheet stage.

The Strategic Imperative of IP for Deep Tech Funding

Deep tech companies are valued primarily on intangible assets: the patents, trade secrets, and proprietary data that underpin the technology. Guidance aimed at IP-backed startups argues that founders who treat IP as a legal task to complete, rather than a strategic pillar of the fundraising narrative, "spectacularly fail to leverage their IP." To a specialist investor, the same guidance contends, an IP strategy signals business acumen, technical depth, and the ability to build a durable monopoly around the invention.

That framing matters because investors do not simply verify that patents exist. Reporting on venture capital due diligence in the life sciences—where IP scrutiny is similarly intense—describes investors evaluating the strength, scope, and strategic positioning of the entire portfolio, and relying on strong IP to assess valuation, risk, and commercialization potential. The same principle extends to deep tech broadly: the portfolio is evidence of defensibility, and defensibility is what justifies the price.